Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma

Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma

Abstract Background Cabozantinib, a standard of care metastatic renal cell carcinoma (mRCC), may be associated with weight and muscle loss. These effects of new generation VEGFR tyrosine kinase inhibitor on muscle mass loss are poorly described. Methods All cabozantinib‐treated mRCC patients from Ja...

Full description

Bibliographic Details
Main Authors: Emeline Colomba, Carolina Alves Costa Silva, Gwénaël Le Teuff, Jamie Elmawieh, Daniel Afonso, Axelle Benchimol‐Zouari, Annalisa Guida, Lisa Derosa, Ronan Flippot, Bruno Raynard, Bernard Escudier, François Bidault, Laurence Albiges
Format: Article
Language:English
Published: Wiley 2022-10-01
Series:Journal of Cachexia, Sarcopenia and Muscle
Subjects:
Cabozantinib
Weight loss
Muscle wasting
Sarcopenia
Metastatic renal cell carcinoma
Online Access:https://doi.org/10.1002/jcsm.13021

Internet

https://doi.org/10.1002/jcsm.13021

Similar Items